Eli Lilly (LLY) Receives FDA Approval for Foundayo Weight Management Pill [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
of Foundayo (orforglipron), the first once-daily GLP-1 receptor agonist pill for chronic weight management that can be taken without food or water restrictions. Indicated for adults with obesity or overweight with weight-related comorbidities, the medication is designed to be used alongside a reduced-calorie diet and increased physical activity. Foundayo will be available starting April 6, through LillyDirect and retail pharmacies, with a pricing structure starting at $25 per month for those with commercial insurance and $149 for self-pay patients. The approval is supported by the ATTAIN-1 clinical trial, where participants on the highest dose lost an average of 27.3 pounds (12.4%) over 72 weeks, compared to just 2.2 pounds for the placebo group. Beyond weight reduction, the trial showed improvements in cardiovascular risk markers, such as systolic blood pressure and cholesterol levels. Unlike previous oral GLP-1 treatments, Foundayo's small-molecule formulation allows for flexibl
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Lilly vs JPMorgan: Which Hits a $1 Trillion Market Cap First? [Yahoo! Finance]Yahoo! Finance
- Novo Says Weight-Loss Boom Is Just Beginning [Yahoo! Finance]Yahoo! Finance
- Eli Lilly's Path to $1 Trillion Runs Directly Through the AI Boom [Yahoo! Finance]Yahoo! Finance
- 25th Annual Bio-IT World Conference & Expo in Boston Leads the Conversation on Operationalizing AI Across Real-World Drug Discovery Environments [Yahoo! Finance]Yahoo! Finance
- Eli Lilly and Company (LLY) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=LLY&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "stMarketBeat
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/20/26 - Form DEFA14A
- 3/20/26 - Form DEF
- LLY's page on the SEC website